Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 6/2013

01-06-2013 | Educational Series – Blue Series

Nanoemulsions and nanoparticles for non-melanoma skin cancer: effects of lipid materials

Authors: P. Severino, J. F. Fangueiro, S. V. Ferreira, R. Basso, M. V. Chaud, M. H. A. Santana, A. Rosmaninho, E. B. Souto

Published in: Clinical and Translational Oncology | Issue 6/2013

Login to get access

Abstract

Basal cell carcinomas and squamous cell carcinomas are non-melanoma skin cancers reported to be among the most common malignancies, being responsible for high human morbidity. Conventional chemotherapy applied to these conditions shows non-specific targeting, thus severe adverse side effects are also commonly reported. New therapeutic strategies based on nanoparticulates technology have emerged as alternatives for site specific chemotherapy. Among the different types of nanoparticulates, lipid nanoemulsions and nanoparticles have several advantages for topical delivery of poorly soluble chemotherapeutics. These particles show sustained drug release and protection of loaded drugs from chemical degradation. This technology is promising to enhance the intracellular concentration of drugs and consequently reduce the cytotoxicity of skin chemotherapy.
Literature
1.
Prow TW, Grice JE, Lin LL, Faye R, Butler M, Becker W et al (2011) Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev 63(6):470–491PubMedCrossRef
2.
Garduno-Ramirez ML, Clares B, Dominguez-Villegas V, Peraire C, Ruiz MA, Garcia ML et al (2012) Skin permeation of cacalol, cacalone and 6-epi-cacalone sesquiterpenes from a nanoemulsion. Nat Prod Commun 7(7):821–823PubMed
3.
Chen Y, Wu Q, Zhang Z, Yuan L, Liu X, Zhou L (2012) Preparation of curcumin-loaded liposomes and evaluation of their skin permeation and pharmacodynamics. Molecules 17(5):5972–5987PubMedCrossRef
4.
Chen YC, Liu DZ, Liu JJ, Chang TW, Ho HO, Sheu MT (2012) Development of terbinafine solid lipid nanoparticles as a topical delivery system. Int J Nanomedicine 7:4409–4418PubMed
5.
Desai P, Patlolla RR, Singh M (2011) Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol Membr Biol 27(7):247–259CrossRef
6.
Chen Y, Zhou L, Yuan L, Zhang ZH, Liu X, Wu Q (2012) Formulation, characterization, and evaluation of in vitro skin permeation and in vivo pharmacodynamics of surface-charged tripterine-loaded nanostructured lipid carriers. Int J Nanomed 7:3023–3033
7.
Gupta M, Vyas SP (2012) Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis. Chem Phys Lipids 165(4):454–461
8.
Estella-Hermoso de Mendoza A, Campanero MA, Mollinedo F, Blanco-Prieto MJ (2009) Lipid nanomedicines for anticancer drug therapy. J Biomed Nanotechnol 5(4):323–343PubMedCrossRef
9.
Pawar KR, Babu RJ (2010) Polymeric and lipid-based materials for topical nanoparticle delivery systems. Crit Rev Ther Drug Carrier Syst 27(5):419–459PubMedCrossRef
10.
de Leeuw J, de Vijlder HC, Bjerring P, Neumann HA (2009) Liposomes in dermatology today. J Eur Acad Dermatol Venereol 23(5):505–516PubMedCrossRef
11.
Pardeike J, Hommoss A, Muller RH (2009) Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 366(1–2):170–184PubMedCrossRef
12.
Souto EB, Muller RH (2008) Cosmetic features and applications of lipid nanoparticles (SLN, NLC). Int J Cosmet Sci 30(3):157–165PubMedCrossRef
13.
Roy SD, Gutierrez M, Flynn GL, Cleary GW (1996) Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design. J Pharm Sci 85(5):491–495PubMedCrossRef
14.
Lee SH, Jeong SK, Ahn SK (2006) An update of the defensive barrier function of skin. Yonsei Med J 47(3):293–306PubMedCrossRef
15.
Schittek B (2011) The antimicrobial skin barrier in patients with atopic dermatitis. Curr Probl Dermatol 41:54–67PubMedCrossRef
16.
Baroli B (2009) Penetration of nanoparticles and nanomaterials in the skin: fiction or reality? J Pharm Sci 99(1):21–50CrossRef
17.
Passeron T, Ortonne JP (2003) Skin ageing and its prevention. Presse Med 32(31):1474–1482PubMed
18.
Kristl J, Teskac K, Grabnar PA (2010) Current view on nanosized solid lipid carriers for drug delivery to the skin. J Biomed Nanotechnol 6(5):529–542PubMedCrossRef
19.
Bouwstra JA, Honeywell-Nguyen PL, Gooris GS, Ponec M (2003) Structure of the skin barrier and its modulation by vesicular formulations. Prog Lipid Res 42(1):1–36PubMedCrossRef
20.
Cheng KW, Mattheolabakis G, Wong CC, Ouyang N, Huang L, Constantinides PP et al (2012) Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer. Int J Oncol (in press)
21.
Grant WB (2012) On the roles of solar UV irradiance and smoking on the diagnosis of second cancers after diagnosis of melanoma. Dermatoendocrinol 4(1):12–17PubMedCrossRef
22.
Pfeifer GP, Besaratinia A (2011) UV wavelength-dependent DNA damage and human non-melanoma and melanoma skin cancer. Photochem Photobiol Sci 11(1):90–97PubMedCrossRef
23.
Andrade P, Brites MM, Vieira R, Mariano A, Reis JP, Tellechea O et al (2012) Epidemiology of basal cell carcinomas and squamous cell carcinomas in a Department of Dermatology: a 5 year review. An Bras Dermatol 87(2):212–219PubMedCrossRef
24.
Clarke P (2012) Nonmelanoma skin cancers—treatment options. Aust Fam Physician 41(7):476–480PubMed
25.
26.
Grachtchouk M, Pero J, Yang SH, Ermilov AN, Michael LE, Wang A et al (2011) Basal cell carcinomas in mice arise from hair follicle stem cells and multiple epithelial progenitor populations. J Clin Invest 121(5):1768–1781PubMedCrossRef
27.
28.
Florence ME, Massuda JY, Brocker EB, Metze K, Cintra ML, Souza EM (2011) Angiogenesis in the progression of cutaneous squamous cell carcinoma: an immunohistochemical study of endothelial markers. Clinics (Sao Paulo) 66(3):465–468CrossRef
29.
Samarasinghe V, Madan V, Lear JT (2011) Management of high-risk squamous cell carcinoma of the skin. Expert Rev Anticancer Ther 11(5):763–769PubMedCrossRef
30.
31.
Kruger K, Blume-Peytavi U, Orfanos CE (1999) Basal cell carcinoma possibly originates from the outer root sheath and/or the bulge region of the vellus hair follicle. Arch Dermatol Res 291(5):253–259PubMedCrossRef
32.
Patel RV, Frankel A, Goldenberg G (2011) An update on nonmelanoma skin cancer. J Clin Aesthet Dermatol 4(2):20–27PubMed
33.
Alimoglu Y, Kilic E, Mercan H, Inci E (2011) Metastatic basal cell carcinoma. J Craniofac Surg 22(3):1134–1136PubMedCrossRef
34.
Panelos J, Tarantini F, Paglierani M, Di Serio C, Maio V, Pellerito S et al (2008) Photoexposition discriminates Notch 1 expression in human cutaneous squamous cell carcinoma. Mod Pathol 21(3):316–325PubMedCrossRef
35.
Bolshakov S, Walker CM, Strom SS, Selvan MS, Clayman GL, El-Naggar A et al (2003) p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res 9(1):228–234PubMed
36.
Renzi C, Mastroeni S, Mannooranparampil TJ, Passarelli F, Caggiati A, Potenza C et al (2010) Delay in diagnosis and treatment of squamous cell carcinoma of the skin. Acta Derm Venereol 90(6):595–601PubMedCrossRef
37.
Yanofsky VR, Mercer SE, Phelps RG (2011) Histopathological variants of cutaneous squamous cell carcinoma: a review. J Skin Cancer 2011:210813PubMed
38.
Sidoroff A, Thaler P (2010) Taking treatment decisions in non-melanoma skin cancer—the place for topical photodynamic therapy (PDT). Photodiagn Photodyn Ther 7(1):24–32CrossRef
39.
Lien MH, Sondak VK (2011) Nonsurgical treatment options for basal cell carcinoma. J Skin Cancer 2011:571734PubMed
40.
O’Bryan KW, Ratner D (2011) The role of targeted molecular inhibitors in the management of advanced nonmelanoma skin cancer. Semin Cutan Med Surg 30(1):57–61PubMedCrossRef
41.
Ackroyd R, Kelty C, Brown N, Reed M (2001) The history of photodetection and photodynamic therapy. Photochem Photobiol 74(5):656–669PubMedCrossRef
42.
Weinstock MA, Bingham SF, Digiovanna JJ, Rizzo AE, Marcolivio K, Hall R et al (2012) Tretinoin and the prevention of keratinocyte carcinoma (Basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol 132(6):1583–1590PubMedCrossRef
43.
Chen TM, Rosen T, Orengo I (2002) Treatment of a large superficial basal cell carcinoma with 5% imiquimod: a case report and review of the literature. Dermatol Surg 28(4):344–346PubMedCrossRef
44.
Wu PA, Stern RS (2012) Topical tretinoin, another failure in the pursuit of practical chemoprevention for non-melanoma skin cancer. J Investig Dermatol 132(6):1532–1535PubMedCrossRef
45.
Osiecka B, Jurczyszyn K, Symonowicz K, Bronowicz A, Ostasiewicz P, Czapinska E et al (2010) In vitro and in vivo matrix metalloproteinase expression after photodynamic therapy with a liposomal formulation of aminolevulinic acid and its methyl ester. Cell Mol Biol Lett 15(4):630–650PubMedCrossRef
46.
Barolet D, Boucher A (2011) No-needle jet intradermal aminolevulinic Acid photodynamic therapy for recurrent nodular Basal cell carcinoma of the nose: a case report. J Skin Cancer 2011:790509PubMed
47.
Jefford M, Kiffer JD, Somers G, Daniel FJ, Davis ID (2004) Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg 74(8):704–705PubMedCrossRef
48.
Teskac K, Kristl J (2010) The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm 390(1):61–69PubMedCrossRef
49.
Shi G, Rao L, Yu H, Xiang H, Yang H, Ji R (2008) Stabilization and encapsulation of photosensitive resveratrol within yeast cell. Int J Pharm 349(1–2):83–93PubMedCrossRef
50.
Rigel DS, Torres AM, Ely H (2008) Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report. J Drugs Dermatol 7(1 Suppl 1):s15–s16PubMed
51.
Dragicevic-Curic N, Winter S, Krajisnik D, Stupar M, Milic J, Graefe S et al (2010) Stability evaluation of temoporfin-loaded liposomal gels for topical application. J Liposome Res 20(1):38–48PubMedCrossRef
52.
Henkin RI (2012) Vismodegib in advanced basal-cell carcinoma. N Engl J Med 367(10):969–971CrossRef
53.
Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD et al (2012) Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366(23):2171–2179PubMedCrossRef
54.
Amini S, Viera MH, Valins W, Berman B (2010) Nonsurgical innovations in the treatment of nonmelanoma skin cancer. J Clin Aesthet Dermatol 3(6):20–34
55.
Smith V, Walton S (2011) Treatment of facial basal cell carcinoma: a review. J Skin Cancer 2011:380371PubMed
56.
Lambert T, Mullinax K, Smith J (2006) A case of an adverse reaction to topical 5-fluorouracil in irradiated skin. J Drugs Dermatol 5(3):282–283PubMed
57.
Hosmer JM, Shin SH, Nornoo A, Zheng H, Lopes LB (2010) Influence of internal structure and composition of liquid crystalline phases on topical delivery of paclitaxel. J Pharm Sci (in press)
58.
Paolino D, Celia C, Trapasso E, Cilurzo F, Fresta M (2012) Paclitaxel-loaded ethosomes(R): potential treatment of squamous cell carcinoma, a malignant transformation of actinic keratoses. Eur J Pharm Biopharm 81(1):102–112PubMedCrossRef
59.
Ndiaye M, Philippe C, Mukhtar H, Ahmad N (2011) The grape antioxidant resveratrol for skin disorders: promise, prospects, and challenges. Arch Biochem Biophys 508(2):164–170PubMedCrossRef
60.
Roy P, Kalra N, Prasad S, George J, Shukla Y (2009) Chemopreventive potential of resveratrol in mouse skin tumors through regulation of mitochondrial and PI3K/AKT signaling pathways. Pharm Res 26(1):211–217PubMedCrossRef
61.
Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW et al (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275(5297):218–220PubMedCrossRef
62.
Stanley MA (2002) Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 27(7):571–577PubMedCrossRef
63.
Amaria RN, Bowles DW, Lewis KD, Jimeno A (2012) Vismodegib in basal cell carcinoma. Drugs Today (Barc) 48(7):459–467
64.
Dirix L, Rutten A (2012) Vismodegib: a promising drug in the treatment of basal cell carcinomas. Future Oncol 8(8):915–928PubMedCrossRef
65.
Paszko E, Ehrhardt C, Senge MO, Kelleher DP, Reynolds JV (2011) Nanodrug applications in photodynamic therapy. Photodiagn Photodyn Ther 8(1):14–29CrossRef
66.
Durbec M, Cosmidis A, Fuchsmann C, Ramade A, Ceruse P (2012) Efficacy and safety of photodynamic therapy with temoporfin in curative treatment of recurrent carcinoma of the oral cavity and oropharynx. Eur Arch Otorhinolaryngol (in press)
67.
Bechet D, Couleaud P, Frochot C, Viriot ML, Guillemin F, Barberi-Heyob M (2008) Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol 26(11):612–621PubMedCrossRef
68.
Krishnan G, Roberts MS, Grice J, Anissimov YG, Benson HA (2010) Enhanced transdermal delivery of 5-aminolevulinic acid and a dipeptide by iontophoresis. Biopolymers 96(2):166–171CrossRef
69.
Lee Y, Baron ED (2011) Photodynamic therapy: current evidence and applications in dermatology. Semin Cutan Med Surg 30(4):199–209PubMedCrossRef
70.
Tran MA, Watts RJ, Robertson GP (2009) Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell Melanoma Res 22(4):388–399PubMedCrossRef
71.
Goutayer M, Dufort S, Josserand V, Royere A, Heinrich E, Vinet F et al (2010) Tumor targeting of functionalized lipid nanoparticles: assessment by in vivo fluorescence imaging. Eur J Pharm Biopharm 75(2):137–147PubMedCrossRef
72.
Morgillo F, Lee HY (2005) Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist Updat 8(5):298–310PubMedCrossRef
73.
Cho KJ, Wang X, Nie S, Chen ZG, Shin DM (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14:1310–1316PubMedCrossRef
74.
Kairemo K, Erba P, BergströK J, Pauwels EKJ (2008) Nanoparticles in cancer. Curr Radiopharm 1:30–36CrossRef
75.
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751–760
76.
Ryman-Rasmussen JP, Riviere JE, Monteiro-Riviere NA (2007) Variables influencing interactions of untargeted quantum dot nanoparticles with skin cells and identification of biochemical modulators. Nano Lett 7(5):1344–1348PubMedCrossRef
77.
Verma DD, Verma S, Blume G, Fahr A (2003) Particle size of liposomes influences dermal delivery of substances into skin. Int J Pharm 258(1–2):141–151PubMedCrossRef
78.
Marie-Alexandrine B, Stephanie B, Yves C (2011) Nanoparticles through the skin: managing conflicting results of inorganic and organic particles in cosmetics and pharmaceutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol (in press)
79.
Hia J, Nasir A (2011) Photonanodermatology: the interface of photobiology, dermatology and nanotechnology. Photodermatol Photoimmunol Photomed 27(1):2–9PubMedCrossRef
80.
Kogan A, Garti N (2006) Microemulsions as transdermal drug delivery vehicles. Adv Colloid Interface Sci 123–126:369–385PubMedCrossRef
81.
Spernath A, Aserin A (2006) Microemulsions as carriers for drugs and nutraceuticals. Adv Colloid Interface Sci 128–130:47–64PubMedCrossRef
82.
Anton N, Vandamme TF (2010) Nano-emulsions and micro-emulsions: clarifications of the critical differences. Pharm Res 28(5):978–985PubMedCrossRef
83.
Araujo FA, Kelmann RG, Araujo BV, Finatto RB, Teixeira HF, Koester LS (2010) Development and characterization of parenteral nanoemulsions containing thalidomide. Eur J Pharm Sci 42(3):238–245PubMedCrossRef
84.
Tagne JB, Kakumanu S, Nicolosi RJ (2008) Nanoemulsion preparations of the anticancer drug dacarbazine significantly increase its efficacy in a xenograft mouse melanoma model. Mol Pharm 5(6):1055–1063PubMedCrossRef
85.
Shakeel F, Ramadan W (2010) Transdermal delivery of anticancer drug caffeine from water-in-oil nanoemulsions. Colloids Surf B Biointerfaces 75(1):356–362PubMedCrossRef
86.
Araujo LM, Thomazine JA, Lopez RF (2010) Development of microemulsions to topically deliver 5-aminolevulinic acid in photodynamic therapy. Eur J Pharm Biopharm 75(1):48–55PubMedCrossRef
87.
Lin C–C, Lin H-Y, Chen H-C, Yu M-W, Lee M-H (2009) Stability and characterisation of phospholipid-based curcumin-encapsulated microemulsions. Food Chem 116(4):923–928CrossRef
88.
Liu CH, Chang FY, Hung DK (2011) Terpene microemulsions for transdermal curcumin delivery: effects of terpenes and cosurfactants. Colloids Surf B Biointerfaces 82(1):63–70PubMedCrossRef
89.
Kakumanu S, Tagne JB, Wilson TA, Nicolosi RJ (2011) A nanoemulsion formulation of dacarbazine reduces tumor size in a xenograft mouse epidermoid carcinoma model compared to dacarbazine suspension. Nanomedicine 7(3):277–283PubMedCrossRef
90.
Kristl J, Teskac K, Milek M, Mlinaric-Rascan I (2008) Surface active stabilizer tyloxapol in colloidal dispersions exerts cytostatic effects and apoptotic dismissal of cells. Toxicol Appl Pharmacol 232(2):218–225PubMedCrossRef
91.
Schafer-Korting M, Mehnert W, Korting HC (2007) Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev 59(6):427–443PubMedCrossRef
92.
Singhal GB, Patel RP, Prajapati BG, Patel NA (2011) Solid lipid nanoparticles and nano lipid carriers: as novel solid lipid based drug carrier. Int Res J Pharm 2(2):20–52
93.
Mudshinge SR, Deore AB, Patil S, Bhalgat CM (2011) Nanoparticles: emerging carriers for drug delivery. Saudi Pharm J 19(3):129–141CrossRef
94.
Nikolic S, Keck CM, Anselmi C, Müller RH (2011) Skin photoprotection improvement: synergistic interaction between lipid nanoparticles and organic UV filters. Int J Pharm 414(1–2):276–284PubMedCrossRef
95.
Mandawgade SD, Patravale VB (2008) Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int J Pharm 363(1–2):132–138PubMedCrossRef
96.
Shah KA, Date AA, Joshi MD, Patravale VB (2007) Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm 345(1–2):163–171PubMedCrossRef
97.
Abdel-Mottaleb MMA, Neumann D, Lamprecht A (2011) Lipid nanocapsules for dermal application: a comparative study of lipid-based versus polymer-based nanocarriers. Eur J Pharm Biopharm (In Press, Corrected Proof)
98.
David S, Carmoy N, Resnier P, Denis C, Misery L, Pitard B et al (2011) In vivo imaging of DNA lipid nanocapsules after systemic administration in a melanoma mouse model. Int J Pharm 423(1):108–115PubMedCrossRef
99.
Weiss MB, Aplin AE (2010) Paying “particle” attention to novel melanoma treatment strategies. J Invest Dermatol 130(12):2699–2701PubMedCrossRef
100.
Huynh NT, Passirani C, Saulnier P, Benoit JP (2009) Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm 379(2):201–209PubMedCrossRef
101.
Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP (2002) A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res 19(6):875–880PubMedCrossRef
102.
Ourique AF, Melero A, de Bona da Silva C, Schaefer UF, Pohlmann AR, Guterres SS et al (2011) Improved photostability and reduced skin permeation of tretinoin: development of a semisolid nanomedicine. Eur J Pharm Biopharm 79(1):95–101
Metadata
Title
Nanoemulsions and nanoparticles for non-melanoma skin cancer: effects of lipid materials
Authors
P. Severino
J. F. Fangueiro
S. V. Ferreira
R. Basso
M. V. Chaud
M. H. A. Santana
A. Rosmaninho
E. B. Souto
Publication date
01-06-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 6/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0982-0

Other articles of this Issue 6/2013

Clinical and Translational Oncology 6/2013 Go to the issue

Erratum

Erratum to: Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

Research Article

Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma

Research Article

Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients

Research Article

Comparisons of 5-aminolevulinic acid photodynamic therapy and after-loading radiotherapy in vivo in cervical cancer

Research Article

Intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma: topography of locoregional recurrences and long-term outcomes

Research Article

Pilot study of feasibility and dosimetric comparison of prone versus supine breast radiotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits